CHICAGO and ALLSCHWIL, Switzerland, Oct. 9, 2006 (PRIMEZONE) -- Actelion Ltd (Other OTC:ALIOF) (SWX:ATLN) announced today that the detailed analysis of the dose-finding study CONSCIOUS-1 (Clazosentan to Overcome Neurological iSChemia and Infarct OccUrring after Subarachnoid hemorrhage) has been presented at the Congress of Neurological Surgeons (CNS) in Chicago by R. Loch Macdonald, MD, PhD, Professor of Surgery and Radiation & Cellular Oncology at University of Chicago Hospitals. Dr. Macdonald is a member of the study steering committee.
